Cargando…

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?

INTRODUCTION: In 2017, neoadjuvant, cisplatin-based chemotherapy followed by radical cystectomy (RC) is considered the gold standard therapy for muscle-invasive bladder based on randomized controlled trials. Across all tumor stages, this approach has been associated with the highest rates of disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smelser, Woodson Wade, Austenfeld, Marcus A., Holzbeierlein, Jeffrey Maxwell, Lee, Eugene Kang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396398/ https://www.ncbi.nlm.nih.gov/pubmed/28469298 http://dx.doi.org/10.4103/iju.IJU_279_16

Ejemplares similares

Where are we now and where are we heading in muscle invasive bladder cancer
por: Ku, Ja Hyeon, et al.
Publicado: (2020)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
por: Pardo, Juan Carlos, et al.
Publicado: (2020)

Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer
por: Joung, Jae Young, et al.
Publicado: (2008)

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016)

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
por: Hamad, Judy, et al.
Publicado: (2020)

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder
por: Michaelson, M D, et al.
Publicado: (2004)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer
por: Zhiyu, Zhang, et al.
Publicado: (2021)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Stem Cell Therapy in Bladder Dysfunction: Where Are We? And Where Do We Have to Go?
por: Kim, Jae Heon, et al.
Publicado: (2013)

A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer
por: Portner, R., et al.
Publicado: (2021)

Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes
por: Garcia, Maurice M., et al.
Publicado: (2014)

Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017
por: Pradère, Benjamin, et al.
Publicado: (2017)

Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes
por: Garcia, Maurice M., et al.
Publicado: (2016)

Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience
por: Gerardi, Marianna A., et al.
Publicado: (2016)

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
por: Koga, Fumitaka, et al.
Publicado: (2018)

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review
por: Fukushima, Hiroshi, et al.
Publicado: (2022)

Are we following the guidelines on non-muscle invasive bladder cancer?
por: Reis, Leonardo Oliveira, et al.
Publicado: (2016)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review
por: Bos, Manouk K., et al.
Publicado: (2014)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
por: El-Taji, Omar M. S., et al.
Publicado: (2016)

Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients
por: Arafat, Waleed, et al.
Publicado: (2016)

The Significance of Neutrophil-to-Lymphocyte Ratio and Combined Chemoradiotherapy in Patients Undergoing Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
por: Wu, Chun-Te, et al.
Publicado: (2020)

Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer—a valid option for cisplatin-unfit patients?
por: Arnold, C. R., et al.
Publicado: (2021)

Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer
por: Mohamed, Dalia O., et al.
Publicado: (2021)

Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: Shahbaz, Muhammad, et al.
Publicado: (2020)

The genetic patterns of bladder cancer. Where do we stand now?
por: Salagierski, Maciej
Publicado: (2013)

Small-cell carcinoma of the urinary bladder: where do we stand?
por: GHERVAN, LIVIU, et al.
Publicado: (2017)

En-bloc Laser Resection of Bladder Tumors: Where Are We Now?
por: Creta, Massimiliano, et al.
Publicado: (2022)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
por: Agrawal, Chinmayee, et al.
Publicado: (2020)

Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: Current landscape and future directions
por: Sun, Xinghui, et al.
Publicado: (2023)

Tumor heterogeneity in muscle-invasive bladder cancer
por: Kang, Ho Won, et al.
Publicado: (2020)

Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
por: Zhu, Huier, et al.
Publicado: (2019)

Detection of circulating tumor DNA for advanced bladder cancer: where are we going?
por: Morales-Barrera, Rafael, et al.
Publicado: (2018)

Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review
por: Lemiński, Artur, et al.
Publicado: (2023)

AB007. Bladder-sparing treatments for muscle-invasive bladder cancer
por: Li, Shengwen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7d761if8e4d3l8fnh5epkb91g3